^
Association details:
| Biomarker: | XPO1 R749Q |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Xpovio (selinexor) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The biological role and mechanisms of XPO1 R749Q mutation in colon cancer
Published date:
03/09/2022
Excerpt:
In vivo observations in mice xenografted with XPO1 R749Q mutant HCT116 cells showed moderate tumor response to selinexor or irinotecan monotherapies but prolonged tumor responses to combination therapy.
Secondary therapy:
irinotecan
